Former host of the “Rush Limbaugh Show” James Golden, aka Bo Snerdley, discusses why he believes President-elect Donald Trump ...

CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter ...

Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in ...

Editor’s note: Dr. Jill Grimes is author of “The Ultimate College Student Health Handbook: Your Guide for Everything From ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

President-elect Donald Trump's return to the White House could mean a push to revoke a federal directive for hospitals to ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Assessment showed the symptoms were not related to its shot, the company said. "The information provided to the FDA supported ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, ...